OR WAIT null SECS
July 27, 2023
MilliporeSigma has invested $25 million to expand its cell culture media production facility in Lenexa, Kan.
July 02, 2023
The choice of expression system requires wise consideration of product complexities.
June 15, 2023
The bioreactor scaler tool helps scaling between development and manufacturing and to de-risk scaling activities and ensure product quality.
April 02, 2023
The innovation of going from stainless-steel bioreactors to fixed-bed bioreactors shows an evolution in upstream optimization.
October 12, 2022
Using a predictive modeling approach can help tighten up operator control over bioprocessing, which in turn can increase bioreactor output.
October 10, 2022
Cytiva’s acquisition of CEVEC Pharmaceuticals strengthens the company’s cell line development and biomanufacturing capabilities.
October 02, 2022
The industry revisits the pros and cons of microbial fermentation at scale for biotherapeutics.
August 02, 2022
Successful scale-up and BLA filings for products manufactured by microbial biomanufacturing require strategic planning.
July 02, 2022
Industry adoption of plant-made biologics remains slow, but plant-based technology gains an advantage by mainstream exposure.
June 27, 2022
MilliporeSigma’s new BioContinuum Seed Train Platform offering enables a fully closed bioprocessing environment for both fed-batch and perfusion N-production.